Javascript must be enabled to continue!
Phosphoproteomic analysis reveals the diversity of signaling behind ErbB inhibitor-induced phenotypes
View through CrossRef
AbstractThe impact of kinase inhibitors on the phosphoproteome has been rarely investigated at a whole organism level. Here we performed a phosphoproteomic analysis in embryonic zebrafish to identify the signaling pathways perturbed by ErbB receptor tyrosine kinase inhibitors at the organism level. The phosphorylation of proteins associated with the PI3K/Akt, p38 MAPK, Notch, Hippo/Yap and β-catenin signaling pathways were differentially regulated by the ErbB inhibitors. Gene set enrichment analyses indicated differential neurological and myocardial phenotypes of different ErbB inhibitors. To assess the neurological and myocardial effects, motility and ventricle growth assays were performed on zebrafish embryos treated with the ErbB and downstream signaling pathway inhibitors. The treatment with the inhibitors targeting the PI3K/Akt, p38 MAPK, and Notch signaling pathways along with the ErbB inhibitors AG1478 and Lapatinib perturbed the overall movement and ventricle wall growth of zebrafish embryos. Taken together, these results indicate that inhibitors with the same primary targets can affect different signaling pathways while eliciting similar physiological phenotypes.
Cold Spring Harbor Laboratory
Title: Phosphoproteomic analysis reveals the diversity of signaling behind ErbB inhibitor-induced phenotypes
Description:
AbstractThe impact of kinase inhibitors on the phosphoproteome has been rarely investigated at a whole organism level.
Here we performed a phosphoproteomic analysis in embryonic zebrafish to identify the signaling pathways perturbed by ErbB receptor tyrosine kinase inhibitors at the organism level.
The phosphorylation of proteins associated with the PI3K/Akt, p38 MAPK, Notch, Hippo/Yap and β-catenin signaling pathways were differentially regulated by the ErbB inhibitors.
Gene set enrichment analyses indicated differential neurological and myocardial phenotypes of different ErbB inhibitors.
To assess the neurological and myocardial effects, motility and ventricle growth assays were performed on zebrafish embryos treated with the ErbB and downstream signaling pathway inhibitors.
The treatment with the inhibitors targeting the PI3K/Akt, p38 MAPK, and Notch signaling pathways along with the ErbB inhibitors AG1478 and Lapatinib perturbed the overall movement and ventricle wall growth of zebrafish embryos.
Taken together, these results indicate that inhibitors with the same primary targets can affect different signaling pathways while eliciting similar physiological phenotypes.
Related Results
Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells
Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells
AbstractThde responsiveness of estrogen receptor (ER)‐positive breast cancer to endocrine therapy is frequently reduced ihd cells over‐expressing c‐erbB‐2. Stimulation of ER suppre...
Critical role for D‐type cyclins in cellular transformation induced by E6/E7 of human papillomavirus type 16 and E6/E7/ErbB‐2 cooperation
Critical role for D‐type cyclins in cellular transformation induced by E6/E7 of human papillomavirus type 16 and E6/E7/ErbB‐2 cooperation
Recently, we reported that E6/E7 of human papillomavirus (HPV) type 16 cooperates with the ErbB‐2 receptor to induce cellular transformation of human normal oral epithelial (NOE) a...
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma
c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma Aims: The c‐erbB‐2 and c‐Met proto‐oncogenes are important for ...
Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
Abstract
Molecular inhibition of the ErbB signaling pathway represents a promising cancer treatment strategy. Preclinical studies suggest that enhancement of anti...
CTNI-08. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE PAN-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION
CTNI-08. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE PAN-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION
Abstract
Mutations causing errant ErbB activation are implicated in many cancers, including tumors correlated with high incidence of CNS metastasis. ErbB family memb...
Cancer Regulator EGFR‑ErbB4 Heterodimer is Stabilized Through Glycans at the Dimeric Interface
Cancer Regulator EGFR‑ErbB4 Heterodimer is Stabilized Through Glycans at the Dimeric Interface
Abstract
The ErbB family of tyrosine kinase receptors is composed of four homologous members, including EGFR (ErbB1/HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). Sin...
Phosphoproteomic profiling reveals signaling pathways modulated by
Annona muricata
leaf extract in oral adenosquamous carcinoma cells
Phosphoproteomic profiling reveals signaling pathways modulated by
Annona muricata
leaf extract in oral adenosquamous carcinoma cells
Abstract
Phosphorylation driven dysregulation of intracellular signaling networks is a central feature of cancer initiation, progression, and the...
Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas
Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas
Objective: To examine the immunohistochemical expression of four members of the type 1 growth factor receptor family in oral squamous cell carcinomas (OSCCs) and to correlate with ...

